about
Targeting the hepatocyte growth factor-cMET axis in cancer therapyThe role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agentsTargeted therapies in development for non-small cell lung cancerMechanisms of action of therapeutic antibodies for cancerEGFR-TKI resistance in NSCLC patients: mechanisms and strategiesXL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells.Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literaturesBiomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRASGlobal expression profile in low grade meningiomas and schwannomas shows upregulation of PDGFD, CDH1 and SLIT2 compared to their healthy tissue.Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic MiceSynergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinibEarly clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.New molecular targeted therapies for advanced non-small-cell lung cancer.Personalizing therapy with targeted agents in non-small cell lung cancerThe HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.Tyrosine kinase inhibitors in lung cancer.Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer.Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancerNovel compounds in the treatment of lung cancer: current and developing therapeutic agents.Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis.Expression and prognostic relevance of MET and phospho-BAD in non-small cell lung cancer.Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.Targeting the MET oncogene in cancer and metastases.Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?Targeting the Met pathway in lung cancer.Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinibTargeting the MET pathway for potential treatment of NSCLC.Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance.MET: a new promising biomarker in non-small-cell lung carcinoma.Emerging targeted therapies in non-small cell lung cancer.Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.Erlotinib for the treatment of brain metastases in non-small cell lung cancer.An intramolecular G-quadruplex structure formed in the human MET promoter region and its biological relevance.Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.Isolation, characterization, and transplantation of cardiac endothelial cells.A novel G-quadruplex motif in the Human MET promoter region.
P2860
Q24606259-69BF73E6-6481-4E32-8EA8-0FFC7569A766Q26823903-E57B74F4-86BF-430B-8227-E746BADD74CAQ27022852-BE4B7AA5-E472-4780-9159-D9BC1D406821Q28385366-F9FF225A-4A7F-482C-9A1B-9F6910C24294Q28394310-E11A664A-F271-416E-BA5B-559404281639Q30428632-F72F2008-626A-4E1D-8375-BCC69958BC55Q33580500-65C0727D-639D-4EFE-9F9F-D3EC2DD731F3Q33748638-AA42C5F6-E17B-43A5-88A4-F0C5B7018130Q34023414-8251D8D1-5550-4E6B-B094-0F0456CF8710Q34556785-65AAFBCF-637D-49D8-9E89-98334117F7CAQ34627751-D3EE1464-8536-456B-9BE8-FC76EF9AE575Q34635475-C420B07B-E6E8-436E-856E-610E8D955865Q35584967-57CFC80E-51A8-4DE5-B2CE-7D1541E2CB45Q35667806-58E38398-C410-4E34-9B6F-AF739F2D087FQ35679361-829DD28C-B1E2-4160-AF2A-76449ADA10C7Q35740444-77334B5E-E060-4AB7-A58E-BD416AA74107Q35908430-D76449D7-1075-4813-8189-49175112830BQ36092910-CB026F42-BDCC-44BC-98EF-37B2992190F9Q36159154-233EC4AC-03A0-4259-BC2B-438B59390043Q36878125-0BEFE064-69E9-4D4A-B2D8-3D00E0731CFCQ36890658-7F4CB302-1538-4F0A-A314-C9FE71D4DFD7Q36953116-82120ACF-9FE5-4601-937C-050EFCEB6868Q37209597-03E37998-07F2-41A9-86DE-18D53C4C9E6EQ37379113-507888C4-56ED-43BD-BA20-E1DD5B5C2C52Q37792116-A24F51BF-086C-483B-8481-C54C476FCD42Q37823422-3A27F079-3185-4BAC-849B-46926D16F348Q37945643-31A9E827-1162-49ED-A3E2-627109DD8EBCQ38002473-44649853-F775-4711-9D02-62A549C50046Q38261315-42D10AB0-6811-4D96-9067-090DEA1299E3Q38297235-AD78E1C6-CD08-4C0D-9DAE-CA90F192311AQ38411480-9C97A7C0-5840-43CF-89AF-A43ACD7850F2Q38419681-15EDCDBD-E386-457D-925D-92C3A87F7109Q38430194-C9C31E0A-29BD-4E4B-8C4F-475685CA35F4Q38653045-2597AB94-4358-4810-9F8E-643306D4ADA8Q38711090-58BD7CCD-D683-4805-98C7-871FDCC5735AQ38770028-83912459-9205-490D-AFB9-00072AF8FD1BQ38878552-1D365643-7E7A-42AA-95AD-0491F1C90178Q40070868-367C96C8-FFF7-48EB-9FB8-769114F4791BQ42911045-A5104CBC-B555-4591-95A6-E9D85CC0AEDEQ47164810-C39CAE74-39EC-4066-9674-6AC4BA89B532
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
MET as a target for treatment of chest tumors
@en
MET as a target for treatment of chest tumors.
@nl
type
label
MET as a target for treatment of chest tumors
@en
MET as a target for treatment of chest tumors.
@nl
prefLabel
MET as a target for treatment of chest tumors
@en
MET as a target for treatment of chest tumors.
@nl
P2860
P1433
P1476
MET as a target for treatment of chest tumors
@en
P2093
Nicole A Cipriani
Oyewale O Abidoye
P2860
P304
P356
10.1016/J.LUNGCAN.2008.06.011
P577
2008-07-30T00:00:00Z